Physician profile
Drew C Ingram
NPI 1750575692
$22,104.09
in general payments reported to CMS, 2019-2025
39 companies · $3,996 in 2025
The $3,996 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $529 · 2021: $1,222 · 2022: $1,446 · 2023: $1,765 · 2024: $2,876 · 2025: $3,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,553 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,552.85 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,152.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,519.09 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,272.72 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $1,072.12 | 2022-2025 | |
| Madrigal Pharmaceuticals | $906.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $899.32 | 2019-2025 | Stelara, Tremfya |
| Nestle Healthcare Nutrition INC. | $798.55 | 2021-2023 | |
| Qol Medical, LLC | $642.25 | 2019-2025 | Sucraid, Sucraid |
| Allergan, INC. | $545.01 | 2019-2020 | |
| Gilead Sciences, INC. | $319.72 | 2019-2024 | |
| Pfizer INC. | $317.05 | 2019-2025 | |
| Celgene Corporation | $288.55 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $255.68 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $205.19 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $194.06 | 2025 | Iqirvo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $169.64 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $164.20 | 2019-2025 | Linzess |
| Biocon Biologics INC | $153.08 | 2024-2025 | Yesintek, Hulio |
| Lilly USA, LLC | $140.07 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $138.27 | 2022-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $126.89 | 2019-2024 | Dificid |
| Shionogi INC | $111.65 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $101.38 | 2025 | Voquezna |
| Romark Laboratories, Lc | $76.28 | 2019-2020 | |
| Ardelyx, INC. | $71.01 | 2022-2024 | Ibsrela |
| Organon LLC | $59.27 | 2023-2025 | Hadlima |
| Ferring Pharmaceuticals INC. | $59.22 | 2019-2024 | Rebyota |
| Olympus America INC. | $55.45 | 2019 | |
| Braintree Laboratories, INC. | $43.73 | 2019-2024 | Sutab |
| Medtronic, INC. | $40.46 | 2023 | Biomedicus |
| Fujifilm Healthcare Americas Corporation | $37.07 | 2025 | |
| Boston Scientific Corporation | $28.09 | 2025 | Cre Pro |
| Vivus LLC | $22.40 | 2019 | |
| Ucb, INC. | $21.94 | 2019 | |
| Novo Nordisk INC | $20.02 | 2025 | Wegovy |
| Redhill Biopharma INC. | $19.55 | 2021 | |
| Endo Pharmaceuticals INC. | $19.44 | 2019 | |
| Celltrion USA INC. | $19.22 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $16.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.